Opigolix

Opigolix
Clinical data
Other namesASP-1707
Routes of
administration		By mouth
Drug classGnRH modulator; GnRH antagonist; Antigonadotropin
Identifiers
IUPAC name
  • (2R)-N'-[5-[3-(2,5-difluorophenyl)-2-(1,3-dihydrobenzimidazol-2-ylidene)-3-oxopropanoyl]-2-fluorophenyl]sulfonyl-2-hydroxypropanimidamide
CAS Number
PubChem CID
UNII
KEGG
Chemical and physical data
FormulaC25H19F3N4O5S
Molar mass544.51 g·mol−1
3D model (JSmol)
SMILES
  • C[C@H](/C(=N/S(=O)(=O)C1=C(C=CC(=C1)C(=O)C(=C2NC3=CC=CC=C3N2)C(=O)C4=C(C=CC(=C4)F)F)F)/N)O
InChI
  • InChI=1S/C25H19F3N4O5S/c1-12(33)24(29)32-38(36,37)20-10-13(6-8-17(20)28)22(34)21(23(35)15-11-14(26)7-9-16(15)27)25-30-18-4-2-3-5-19(18)31-25/h2-12,30-31,33H,1H3,(H2,29,32)/t12-/m1/s1
  • Key:CWNLBPBIFALUQD-GFCCVEGCSA-N

Opigolix (INN, USAN; developmental code name ASP-1707) is a small-molecule, non-peptide, orally active gonadotropin-releasing hormone antagonist (GnRH antagonist) which was under development by Astellas Pharma for the treatment of endometriosis and rheumatoid arthritis.[1][2] It was also under investigation for the treatment of prostate cancer.[1] It reached phase II clinical trials for both endometriosis and rheumatoid arthritis prior to the discontinuation of its development in April 2018.[1]

See also

  • Gonadotropin-releasing hormone receptor § Antagonists

References

  1. 1 2 3 "Opigolix - Astellas Pharma - AdisInsight".
  2. ↑ Ezzati M, Carr BR (2015). "Elagolix, a novel, orally bioavailable GnRH antagonist under investigation for the treatment of endometriosis-related pain". Womens Health (Lond). 11 (1): 19–28. doi:10.2217/whe.14.68. PMID 25581052.


This article is issued from Offline. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.